Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

The first published clinical trial of stem-cell therapy is a tremendous boon to the company leading the experiment—but it’s only a small step forward for the field.

In a paper published this week in The Lancet, scientists from the David Geffen School of Medicine at the University of California, Los Angeles, and from Advanced Cell Technology, in Marlborough, Massachusetts, reported that two patients each safely received injections of embryonic stem cells into an eye.

Stem-cell research in patients suffered a major blow recently, when one leading company, Geron, pulled out of a pioneering spinal cord repair study. The new study is more limited in scope, focusing on treatment that is easier to study and less problematic.  

The new study was written three months after treating the patients, both of whom have degenerative eye diseases and limited sight. Another three months has now passed, and Robert Lanza, chief scientific officer of Advanced Cell Technology, says both are still doing well, with no apparent side effects.

Lanza says Advanced Cell Technology would not commercialize the work itself, but would look to partner with a company that would.

The intent of the study was to show that the treatment is safe, not to look at its effectiveness. But Lanza, the paper, and a related commentary also published in The Lancet all cited the women’s reports of benefits from the procedure. One woman’s vision improved enough to see a hand waved in front of her face; the other climbed from 20/500 to 20/320 on an eye chart.

Kevin Eggan, an associate professor of stem cell and regenerative biology at Harvard University, says he’s surprised that The Lancet published such preliminary results, and that scientists are talking about the treatment’s effectiveness at such an early stage of research.

1 comment. Share your thoughts »

Credit: Advanced Cell Technology

Tagged: Biomedicine, A123 Systems, stem cell science, Geron, stem cell therapy

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me